Presentation is loading. Please wait.

Presentation is loading. Please wait.

Lawrence F. Eichenfield, MD, Lisa Beck, MD 

Published byЕмил Ранковић Modified over 5 years ago

Similar presentations

Presentation on theme: "Lawrence F. Eichenfield, MD, Lisa Beck, MD "— Presentation transcript:

1 Elidel (pimecrolimus) cream 1%: A nonsteroidal topical agent for the treatment of atopic dermatitis 
Lawrence F. Eichenfield, MD, Lisa Beck, MD  Journal of Allergy and Clinical Immunology  Volume 111, Issue 5, Pages (May 2003) DOI: /mai Copyright © 2003 Mosby, Inc. Terms and Conditions

2 Fig. 1 Macrolactams block inflammatory cytokine transcription in activated T cells. Journal of Allergy and Clinical Immunology  , DOI: ( /mai ) Copyright © 2003 Mosby, Inc. Terms and Conditions

3 Fig. 2 Pimecrolimus is different from tacrolimus: lipophilicity distribution. Blue indicates hydrophilic regions; brown indicates lipophilic regions. Journal of Allergy and Clinical Immunology  , DOI: ( /mai ) Copyright © 2003 Mosby, Inc. Terms and Conditions

4 Fig. 3 Elidel pediatric study: percentage of subjects with mild or no pruritus. DB, Double-blind; OL, open label. *P < Reproduced with permission from Eichenfield et al. J Am Acad Dermatol, Vol. 46, Page 500, Figure 4, copyright 2002. Journal of Allergy and Clinical Immunology  , DOI: ( /mai ) Copyright © 2003 Mosby, Inc. Terms and Conditions

5 Fig. 4 Elidel pediatric study: percentage of subjects “clear” or “almost clear” of AD (IGA score 0 or 1). Reproduced with permission from Eichenfield et al. J Am Acad Dermatol, Vol. 46, Page 498, Figure 1, copyright 2002. Journal of Allergy and Clinical Immunology  , DOI: ( /mai ) Copyright © 2003 Mosby, Inc. Terms and Conditions

6 Fig. 5 Elidel pediatric study: EASI mean percentage change from baseline (overall, head, and neck). Reproduced with permission from Eichenfield et al. J Am Acad Dermatol, Vol. 46, Page 500, Figure 3, copyright 2002. Journal of Allergy and Clinical Immunology  , DOI: ( /mai ) Copyright © 2003 Mosby, Inc. Terms and Conditions

7 Fig. 6 Elidel infant study: patients “clear” or “almost clear” (IGA score of 0 or 1) during double-blind (A) and open-label (B) phases. Note: After completion of the double-blind phase (day 43), patients in the vehicle-treated group were switched to pimecrolimus treatment in the open-label phase. Reproduced with permission from Ho et al. J Pediatr, Vol. 142, Page 158, Figure 4, copyright 2003. Journal of Allergy and Clinical Immunology  , DOI: ( /mai ) Copyright © 2003 Mosby, Inc. Terms and Conditions

8 Fig. 7 Elidel infant study: shift in IGA score status from baseline to end point (43 days; double-blind phase). Reproduced with permission from Ho et al. J Pediatr, Vol. 142, Page 158, copyright 2003. Journal of Allergy and Clinical Immunology  , DOI: ( /mai ) Copyright © 2003 Mosby, Inc. Terms and Conditions

9 Fig. 8 Elidel infant study: an example of an Elidel treatment success. Photos were taken at baseline (A) and day 43 (B) . Reproduced with permission from Ho et al. J Pediatr, Vol. 142, Page 157, Figure 3, copyright 2003. Journal of Allergy and Clinical Immunology  , DOI: ( /mai ) Copyright © 2003 Mosby, Inc. Terms and Conditions

10 Fig. 9 Design of long-term study comparing early intervention with Elidel with a conventional AD treatment strategy. Journal of Allergy and Clinical Immunology  , DOI: ( /mai ) Copyright © 2003 Mosby, Inc. Terms and Conditions

11 Fig. 10 Long-term management of pediatric AD with Elidel: patients with 0 flares at 6 and 12 months. Reproduced with permission from Wahn et al. Pediatrics, Vol. 110, Page e29, copyright 2002. Journal of Allergy and Clinical Immunology  , DOI: ( /mai ) Copyright © 2003 Mosby, Inc. Terms and Conditions

12 Fig. 11 Long-term management of pediatric AD: proportion of patients with 0 flares after 6 months by disease severity at baseline. Reproduced with permission from Wahn et al. Pediatrics, Vol. 110, Page e29, Figure 2B, copyright 2002. Journal of Allergy and Clinical Immunology  , DOI: ( /mai ) Copyright © 2003 Mosby, Inc. Terms and Conditions

13 Fig. 12 Long-term management of pediatric AD: Kaplan-Meier estimate of time to first flare. Reproduced with permission from Wahn et al. Pediatrics, Vol. 110, Page e29, Figure 2A, copyright 2002. Journal of Allergy and Clinical Immunology  , DOI: ( /mai ) Copyright © 2003 Mosby, Inc. Terms and Conditions

14 Fig. 13 Long-term management of pediatric AD: median percentage reduction in EASI score over 12 months (Elidel vs conventional therapy). CS, Moderately potent corticosteroid. Reproduced with permission from Wahn et al. Pediatrics, Vol. 110, Page e29, Figure 2B, copyright 2002. Journal of Allergy and Clinical Immunology  , DOI: ( /mai ) Copyright © 2003 Mosby, Inc. Terms and Conditions

Download ppt "Lawrence F. Eichenfield, MD, Lisa Beck, MD "

Similar presentations

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.
Wet Wrap Therapy in Children with Moderate to Severe Atopic Dermatitis in a Multidisciplinary Treatment Program  Noreen Heer Nicol, PhD, RN, FNP, Mark.

Wet Wrap Therapy in Children with Moderate to Severe Atopic Dermatitis in a Multidisciplinary Treatment Program  Noreen Heer Nicol, PhD, RN, FNP, Mark.
Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial 

Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial 
Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.
Evaluation and treatment of allergic fungal sinusitis. II

Evaluation and treatment of allergic fungal sinusitis. II
F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc 

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc 
Different expression of cytokine and membrane molecules by circulating lymphocytes on acute mental stress in patients with atopic dermatitis in comparison.

Different expression of cytokine and membrane molecules by circulating lymphocytes on acute mental stress in patients with atopic dermatitis in comparison.
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children  Mark Boguniewicz, MDa, Virginia C. Fiedler,

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children  Mark Boguniewicz, MDa, Virginia C. Fiedler,
Predominance of type 2 cytokine–producing CD4+ and CD8+ cells in patients with atopic dermatitis  Masatoshi Nakazawa, DVMa, Nakako Sugi, MDb, Hiroshi.

Predominance of type 2 cytokine–producing CD4+ and CD8+ cells in patients with atopic dermatitis  Masatoshi Nakazawa, DVMa, Nakako Sugi, MDb, Hiroshi.
Evaluation and treatment of allergic fungal sinusitis. II

Evaluation and treatment of allergic fungal sinusitis. II
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
Overcoming barriers to nonadherence in asthma treatment

Overcoming barriers to nonadherence in asthma treatment
Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,
Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies  Mark.

Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies  Mark.
Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot.

Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Badrul A. Chowdhury, MD, PhD 

Badrul A. Chowdhury, MD, PhD 
An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

Similar presentations

Ads by Google